Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of PN-232 in Healthy Volunteers
NCT04819620Phase 1Completed
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- May 2021
- Primary completion
- Dec 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PN-232 in inflammatory bowel disease (IBD) and psoriasis (3 arms), sponsored by Protagonist Therapeutics, Inc. Primary endpoint: Safety of PN-232 at 10 days. Started May 2021; status: completed.
02
Drugs
PN-232
03
Conditions
inflammatory bowel disease (IBD)psoriasis
Beyond the preview
Go deeper on NCT04819620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04819620.